

# Immunophenotyping reveals longitudinal changes in circulating immune cells during radium-223 therapy in patients with metastatic castration-resistant prostate cancer

J.H.A. Creemers<sup>1,2,†</sup>, M.J. van der Doelen<sup>3,4,†</sup>, S. van Wilpe<sup>1,3,†</sup>, R. Hermsen<sup>5</sup>, T. Duiveman-de Boer<sup>1</sup>, D.M. Somford<sup>6</sup>, M.J.R. Janssen<sup>7</sup>, J.P.M. Sedelaar<sup>4</sup>, N. Mehra<sup>1,3</sup>, J. Textor<sup>1,8</sup>, H. Westdorp<sup>1,3</sup>

<sup>1</sup> Department of Tumor Immunology, Radboudumc, Nijmegen, The Netherlands

<sup>2</sup> Oncode Institute, Nijmegen, The Netherlands

<sup>3</sup> Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands

<sup>4</sup> Department of Urology, Radboudumc, Nijmegen, The Netherlands

<sup>5</sup> Department of Nuclear Medicine, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands

<sup>6</sup> Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands

<sup>7</sup> Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands

<sup>8</sup> Data Science group, Institute for Computing and Information Sciences, Radboud University, Nijmegen, The Netherlands

<sup>†</sup> These authors contributed equally to this article.

## Corresponding author:

Harm Westdorp, MD, PhD

Departments of Tumor Immunology and Medical Oncology

Radboud University Medical Center

PO Box 9101

6500 HB Nijmegen

The Netherlands

Tel: +31-24-361-0354

Fax: +31-24-361-5025

E-mail: Harm.Westdorp@radboudumc.nl

## ABSTRACT

**Purpose:** Radium-223 improves overall survival (OS) in men with bone metastatic castration-resistant prostate cancer (mCRPC). While the exact mechanism behind this survival benefit remains unclear, radium-induced immunological mechanisms might contribute to the OS advantage. We performed a comprehensive evaluation of the immunological changes in mCRPC patients by phenotyping the peripheral blood mononuclear cells (PBMCs) during radium-223 therapy.

**Experimental Design:** In this prospective, single-arm, exploratory study, PBMCs of 30 mCRPC patients were collected before, during, and after treatment with radium-223. Lymphocyte and monocyte counts were analyzed to get insight into general immune cell trends. Next, we analyzed changes in T cell subsets, myeloid-derived suppressor cells (MDSCs), and immune checkpoint expression using linear regression models. Per subset, the 6-month change (% of baseline) was determined. Bootstrapped 95% confidence intervals were used to measure the degree of uncertainty of our findings.

**Results:** We observed a substantial decrease in absolute lymphocyte counts ( $-0.12 \times 10^9$  cells/L per injection, 95% CI:  $-0.143 - -0.102$ ). Simultaneously, an increase was observed in the proportion of T cells that expressed costimulatory (ICOS) or inhibitory (TIM-3, PD-L1, and PD-1) checkpoint molecules. Moreover, the fraction of two immunosuppressive subsets – the regulatory T cells and the monocytic MDSCs – increased throughout treatment. These findings were not more pronounced in patients with an ALP response during therapy.

**Conclusion:** Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.

54 **INTRODUCTION**

55 Radium-223 dichloride (radium-223) was registered in 2013 to treat patients with symptomatic bone  
56 metastatic castration-resistant prostate cancer (mCRPC) based on the results of the phase III,  
57 randomized controlled ALSYMPCA trial. In this trial, radium-223 improved the overall survival (OS)  
58 and prolonged the time to a first symptomatic skeletal event [1].

59 Radium-223 is an alpha-emitting radionuclide that selectively binds to areas with increased bone  
60 turnover, such as bone metastases. Alpha particles are highly ionizing agents with low penetration  
61 power ( $\leq 100 \mu\text{m}$ ) [2]. Their radiation induces double-stranded DNA breaks in adjacent tumor cells,  
62 osteoblasts, and osteoclasts, resulting in tumor cell death and inhibition of pathological bone  
63 formation [3,4]. In models of prostate cancer metastases, radium-223 was found to be deposited at  
64 the bone surface next to the tumor, not within the tumor itself [5]. It is mechanistically largely  
65 unknown how bone metastases respond to radium-223 and, therefore, it is unclear how radium-223  
66 prolongs OS.

67 Immunological mechanisms may contribute to the OS benefit of radium-223. Preclinical studies have  
68 demonstrated that ionizing radiation triggers an immune response via the release of danger-  
69 associated molecular patterns (DAMPs), such as calreticulin. These DAMPs stimulate antigen-  
70 presenting cells to activate cytotoxic T lymphocytes, thereby inducing immunogenic tumor cell death  
71 [6]. A recent *in vitro* study indicates that radium-223, like radiation therapy, can also induce  
72 immunogenic modulation. Radium-223 enhanced T cell-mediated lysis of tumor cells through  
73 upregulation of major histocompatibility complex class I molecules and increased cell surface  
74 expression of calreticulin on tumor cells [7]. Nevertheless, data on the immunological effects of  
75 radium-223 in mCRPC patients is limited to one study that evaluated changes in circulating CD8<sup>+</sup> T  
76 cells during the first 3-4 weeks of radium-223 therapy. This study in fifteen mCRPC patients observed  
77 a decrease in PD-1<sup>+</sup> effector memory CD8<sup>+</sup> T cells during treatment [8]. A better understanding of the  
78 immunological effects of radium-223 might provide a rationale for new treatment strategies,

79 combining radium-223 with immune-based therapies, thereby possibly improving the clinical benefit  
80 of radium-223 therapy in mCRPC.

81 Here we investigated the composition and abundance of circulating peripheral blood mononuclear  
82 cells (PBMCs) of mCRPC patients collected before, during, and after treatment with radium-223. We  
83 postulated that changes in PBMCs could be seen during radium-223, as this has also been described  
84 in patients after external beam radiation [9]. A comprehensive, exploratory analysis was performed  
85 to investigate the longitudinal changes in T cell subsets, myeloid-derived suppressor cell (MDSC)  
86 subsets, and immune checkpoint expression during radium-223 therapy.

87 **METHODS**

88 ***Patient recruitment***

89 This prospective, single-arm, exploratory study included mCRPC patients treated with radium-223 at  
90 the Radboudumc and Canisius-Wilhelmina hospital, Nijmegen, The Netherlands between May 2016  
91 and January 2018. Patients were eligible if they had histologically proven adenocarcinoma of the  
92 prostate, mCRPC with symptomatic bone metastases, and no (history of) visceral metastases.  
93 Patients with a history of a secondary malignancy or auto-immune disease were excluded. Prior  
94 radionuclide treatment and concomitant other anticancer treatments were not allowed except for  
95 luteinizing hormone-releasing hormone agonists or antagonists. The use of low-dose corticosteroids  
96 (maximally 10 mg prednisone daily) was permitted.

97 Written informed consent was obtained from all patients before enrolment. The study was  
98 conducted in accordance with the principles of Good Clinical Practice, the Declaration of Helsinki, and  
99 other applicable local regulations and was approved by the institutional review boards of both  
100 participating centers.

101

102 ***Radium-223 therapy and study-specific procedures***

103 Patients were treated with radium-223 according to daily practice, with radium-223 being  
104 administered intravenously every four weeks at a dose of 55 kBq/kg, with a maximum of six  
105 injections. Laboratory evaluations, including lymphocyte and monocyte counts, were carried out  
106 within four weeks before radium-223 initiation, one week before each subsequent injection, and four  
107 weeks after the end of treatment. Within three months before the start of radium-223 therapy, bone  
108 scintigraphy, and CT or <sup>68</sup>Ga-PSMA-11 PET/CT of the thorax, abdomen, and pelvis were performed. At  
109 baseline and four weeks after the second, fourth, and sixth radium-223 injection, 30ml of blood was  
110 collected in heparin blood collection tubes for immunophenotyping.

111

112

113 ***Blood processing and storage***

114 PBMCs were isolated using Ficoll-Paque gradient centrifugation. After adding Ficoll (Lymphoprep,  
115 Axis-Shield, Dundee, UK), samples were centrifuged at 2100 x g for 20 minutes at room temperature.  
116 The PBMC layer was transferred to a new tube and washed with phosphate-buffered saline (PBS).  
117 Viable cells were counted manually with a Bürker-Türk counting chamber. Cells were resuspended in  
118 culture medium (X-VIVO + 2% human serum) and mixed 1:1 with freezing medium (20% DMSO, 80%  
119 human serum albumin) at a concentration of 2-20 x10<sup>6</sup> viable cells per ml. Cells were aliquoted into  
120 cryogenic vials and stored in liquid nitrogen.

121

122 ***Flow cytometry***

123 PBMCs were thawed rapidly in a 37 °C water bath and diluted in RPMI 1640 media. Cell number and  
124 viability were determined with a hemocytometer using trypan blue. Immunophenotyping of PBMCs  
125 was performed using four antibody panels. We used a T cell panel consisting of antibodies against  
126 CD3, CD4, CD8, CD25, CD45RO, CTLA-4 (CD152), CCR7 (CD197), and FoxP3 (Supplementary Table S1).  
127 In addition, we developed two checkpoint panels. Checkpoint panel 1 included antibodies targeting  
128 CD3, CD4, CD8, LAG-3 (CD223), PD-L1 (CD274), ICOS (CD278), PD-1 (CD279), and TIM-3 (CD366).  
129 Checkpoint panel 2 consisted of a CD3, CD4, CD8, OX-40 (CD134), CTLA-4, PD-L1, PD-1, and TIM-1  
130 (CD365) antibody mix. Lastly, the MDSC panel consisted of antibodies against lineage markers (CD3,  
131 CD19, CD20, CD56), CD11b, CD14, CD15, CD33, PD-L2 (CD273), PD-L1, and HLA-DR. Antibody  
132 specifications are tabulated in Supplementary Table S1. In all panels, fixable viability dye efluor 780  
133 (eBioscience, San Diego, CA, USA) was used to exclude dead cells.  
134 Cells were incubated with fixable viability dye diluted in PBS at 4 °C for 30 minutes. Subsequently,  
135 cells were incubated with an antibody mix, consisting of the cell surface markers diluted in brilliant  
136 staining buffer (BD Biosciences, San Jose, CA, USA). The cells were incubated at 4 °C in the dark for 30  
137 minutes. For intracellular staining, cells stained with the T cell panel were fixed with Fix/Perm  
138 (eBioscience) and incubated for 2 hours at 4 °C. After washing, the cells were resuspended in

139 permeabilization buffer containing antibodies against the intracellular markers anti-FoxP3 and anti-  
140 CTLA-4 and incubated for 30 minutes at 4 °C.  
141 Staining intensity was measured with the FACSLytic (BD Biosciences). Instrument settings were  
142 verified and adjusted before each acquisition using single stainings. Data were analyzed with FlowJo  
143 Software (Tree Star Inc., Ashland, OR, USA). Positive and negative cell populations for each marker  
144 were determined using fluorescence minus one (FMO) controls. The gating strategy is shown in  
145 Supplementary Figure S1. Regarding checkpoint expression, both the percentage of positive cells and  
146 the median fluorescence intensity (MFI) were studied. To minimize the effects of intra-batch  
147 differences, we used the  $\Delta$ MFI, which is defined as the MFI of the test sample minus the MFI of the  
148 negative FMO control. Checkpoint molecules expressed on <1 % of the cell of interest were excluded  
149 from further analyses.

150

### 151 ***Clinical response evaluation***

152 Clinical response was defined as a decline in alkaline phosphatase (ALP) levels of  $\geq 30\%$  from baseline  
153 during therapy, according to the ALSYMPCA study criteria [1]. In addition, PSA responses, radiological  
154 responses, and OS were analyzed. PSA response was defined as a decline of  $\geq 30\%$  during treatment  
155 according to the ALSYMPCA study criteria. Within three months after completion or discontinuation  
156 of therapy, patients underwent radiological evaluation by bone scintigraphy and CT of the thorax,  
157 abdomen, and pelvis. Radiological evaluation of soft tissues was performed according to Response  
158 Evaluation Criteria In Solid Tumors version 1.1 [10], and bone scans were evaluated according to  
159 Prostate Cancer Working Group 3 criteria [11]. OS was defined as the time between the first radium-  
160 223 injection and either death from any cause or the last follow-up. All patients were followed until  
161 death or August 1, 2020.

162

163

164

165 **Data analysis**

166 Exploratory data analyses were performed using R version 3.6.2. The following packages were used  
167 for analyses and visualization: the Tidyverse collection of packages [12], scales [13], cowplot [14],  
168 and ggbeeswarm [15].

169 Lymphocyte and monocyte counts were normalized to adjust for interindividual variation. Cell counts  
170 were normalized per patient as follows: the patients' mean count per cell type was subtracted from  
171 the measurement, and, subsequently, the overall mean of the count of that particular cell type was  
172 added. Linear regression was used to determine the average linear change of the cell counts across  
173 radium-223 injections (Figure 1).

174 Circulating immune cell populations were analyzed for their abundance in peripheral blood during  
175 treatment with radium-223. PBMC-derived percentages of cell populations were pre-processed by a  
176 logit-transformation to enable analysis using linear regression models (except for  $\Delta$ MFI; Figure 2,  
177 Supplementary Figures 3 and 6). Before analysis, the percentage/ $\Delta$ MFI data were normalized per  
178 patient, as described above. (Figure 2A). Immune cell subsets were visualized in grouped scatterplots  
179 per injection number. A linear model was fitted to each immune cell subset to determine the average  
180 change per injection number. Furthermore, checkpoint expression on these cells was also analyzed  
181 using the  $\Delta$ MFI.

182 Next, we quantified longitudinal trends in immune cell subsets as the 6-month change (i.e., change  
183 between the subset's baseline value and the value after the sixth radium-223 injection). We used  
184 percentile bootstrapping to determine the 95% confidence interval (CI) of the 6-month change of an  
185 immune cell subset over time (unit: percentage change relative to baseline; Figure 3, Supplementary  
186 Figures 4 and 7). Specifically, we used 2000 replicates in each bootstrap. Per replicate, we re-sampled  
187 the 30 patients with replacement, normalized the data as described above, and fitted a linear model  
188 to the sample. Next, the 6-month change between these measures was calculated, including a 95% CI  
189 to determine the uncertainty of the bootstrap estimate. Checkpoint expression was analyzed  
190 similarly.

191 In the end, we performed an exploratory subgroup analysis in patients with an ALP response in the  
192 same manner.

193 All R code is available on GitHub: [https://github.com/jeroencreemers/Immunophenotyping-](https://github.com/jeroencreemers/Immunophenotyping-radium223-mCRPC)  
194 [radium223-mCRPC](https://github.com/jeroencreemers/Immunophenotyping-radium223-mCRPC).

195

196

197 **RESULTS**

198 ***Patient characteristics***

199 A total of 35 mCRPC patients were screened, of which 33 patients met the in- and exclusion criteria  
 200 (two patients received concomitant enzalutamide). In the final analysis, three patients were excluded  
 201 because  $\leq 2$  injections of radium-223 were administered, and no follow-up blood withdrawal had  
 202 occurred after discontinuation of treatment. The median age of the study population was 71 years.  
 203 The median number of prior systemic prostate cancer therapies since diagnosis of metastatic  
 204 hormone-sensitive prostate cancer was one (range 0-4). Seventeen patients (57%) had received prior  
 205 docetaxel chemotherapy, and twenty patients (67%) received prior enzalutamide and/or  
 206 abiraterone. Median baseline ALP was 148 IU/l, and the majority of patients (77%) had high volume  
 207 ( $>20$ ) bone metastatic disease. Baseline patient demographics and clinical characteristics are shown  
 208 in Table 1.

209 **Table 1 - Baseline patient demographics and clinical characteristics**

	All patients (N=30)	
Age, years, median (IQR)	71	(64-77)
Time from mCRPC to radium-223, months, median (IQR)	23.9	(10.3-35.3)
Gleason score $\geq 8$ , n (%)	21	(70.0)
Extent of disease, n (%)		
Low volume ( $<6$ bone metastases)	1	(3.3)
Intermediate volume (6-20 bone metastases)	4	(13.3)
High volume ( $>20$ bone metastases)	23	(76.7)
Superscan*	2	(6.7)
Lymph node metastases $\geq 15$ mm	3	(10.0)
Prior systemic therapies		
Median number of prior registered therapies (range)	1	(0-4)
None, n (%)	7	(23.3)
Docetaxel, n (%) <sup>†</sup>	17	(56.7)
Cabazitaxel, n (%)	3	(10.0)
Abiraterone, n (%)	12	(40.0)
Enzalutamide, n (%)	13	(43.3)
Both Abiraterone and Enzalutamide, n (%)	5	(16.7)
Prior symptomatic skeletal event, n (%)	13	(43.3)
Opioid use, n (%)	9	(30.0)
ECOG performance status, n (%)		
ECOG 0	21	(70.0)
ECOG 1	8	(26.7)
ECOG 2	1	(3.3)
Hemoglobin, mmol/L, median (IQR)	7.5	(7.3-8.0)
Platelet count, $\times 10^9/L$ , median (IQR)	239	(192-275)
PSA, ng/ml, median (IQR)	130	(53-374)
ALP, U/L, median (IQR)	148	(100-266)
LDH, U/L, median (IQR)	232	(203-274)

ALP = alkaline phosphatase; mCRPC = castration-resistant prostate cancer; ECOG = Eastern Cooperative Oncology Group; IQR = interquartile range; PSA = prostate-specific antigen

\*Superscan refers to a bone scan showing diffuse, intense skeletal uptake of the tracer without renal and background activity.

<sup>†</sup>Including 3 (10%) patients who were treated with upfront docetaxel for metastatic hormone-naïve prostate cancer

210

211 Twenty-two (73%) patients received all six radium-223 injections. An ALP decline of  $\geq 30\%$  during  
212 therapy was achieved in twenty patients (67%). Four patients (13%) had a PSA decline of  $\geq 30\%$  during  
213 therapy. At the time of analysis, 27 patients (90%) were deceased. Median OS was 13.2 months (95%  
214 CI 10.2-16.2 months). The majority of patients (60%) showed no new bone metastases on bone  
215 scintigraphy after radium-223. Radiological evidence of new pathological lymph node metastases or  
216 development of visceral metastases was found in seven patients (26%) and four patients (15%),  
217 respectively. Clinical outcomes are shown in Supplementary Table 2.

218

219 ***Availability of PBMCs for immunophenotyping***


220 PBMCs for immunophenotyping were available of 30, 29, 26, and 20 patients at baseline and after  
221 two, four, and six injections of radium-223, respectively (Supplementary Figure S2). Missing data was  
222 mostly a consequence of the preterm discontinuation of radium-223 therapy. In one patient (ID-25),  
223 no PBMCs were collected after the second injection of radium-223.

224

225

226 **Absolute lymphocyte and monocyte count**

227 We first analyzed the absolute peripheral lymphocyte and monocyte counts to account for potential  
228 longitudinal variation in mononuclear cells in the population. We fitted linear regression models to  
229 the normalized absolute lymphocyte and monocyte counts per injection number (as a surrogate  
230 marker for time). Lymphocyte counts declined by approximately a factor two during treatment with  
231 radium-223 (Figure 1A; slope:  $-0.12 \times 10^9$  cells/L per injection number, 95% CI:  $-0.143 - -0.102$ ), while  
232 monocyte counts remained relatively stable over the course of treatment (Figure 1B; slope:  $-0.003$   
233  $\times 10^9$  cells/L per injection number, 95% CI:  $-0.012 - 0.005$ ).



234


235 **Figure 1: Normalized absolute mononuclear cell counts during Radium-223 treatment.**  
236 (A) Lymphocyte and (B) monocyte counts at baseline (BL) and after each Radium-223 injection. Red dots  
237 indicate the group means. The blue line represents the fitted linear regression model, including 95% CI.

238

239

240 **Immunophenotype of lymphocyte and monocyte subsets during radium-223 therapy**

241 To investigate longitudinal changes in circulating immune cell subsets in mCRPC patients during  
242 treatment with radium-223, we applied two pre-processing steps to the PBMC data: a logit  
243 transformation and a normalization step (see Methods; Figure 2A).



244

245 **Figure 2: Overview of the analyzed immune cell subsets throughout radium-223 treatment.**  
246 (A) Data pre-processing steps, (B) CD3<sup>+</sup>, CD4<sup>+</sup>, and CD8<sup>+</sup> T cells, (C) Immune checkpoint-expressing T cells, (D)  
247 Memory and effector T cell subsets, (E) Immunosuppressive cell subsets. Red dots indicate the group means. The  
248 blue line represents the fitted linear regression model, including 95% CI.

249

250 We first analyzed the PBMCs for the presence of T cells (CD3<sup>+</sup> cells; Figure 2B). Despite normalization,  
251 substantial variation remained present in the data. Overall, the percentage of T cells within the  
252 population of PBMCs decreased during radium-223 treatment. Within the CD3<sup>+</sup> cells, we  
253 distinguished two T cell subsets: CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells (Figure 2B). No major changes were

254 seen in these subsets. Next, we determined the fraction of CD4<sup>+</sup> and CD8<sup>+</sup> T cells that expressed  
255 costimulatory (OX-40, ICOS, TIM-1) and inhibitory (CTLA-4, LAG-3, PD-L1, PD-1, TIM-3) checkpoint  
256 molecules, respectively (Figure 2C). The expression of OX-40 and LAG-3 on both subsets was  
257 practically absent; hence these checkpoint molecules were omitted from further analyses. Expression  
258 of CTLA-4, TIM-1, and TIM-3 was observed on a small subset (<5%) of CD4<sup>+</sup> and CD8<sup>+</sup> T cells, while  
259 expression of PD-1 (>30%) and PD-L1 (>70%) was more pronounced. A larger proportion of CD4<sup>+</sup> cells  
260 than of CD8<sup>+</sup> cells expressed ICOS (6.6% and <1% at baseline, respectively). The fraction of CD4<sup>+</sup> and  
261 CD8<sup>+</sup> T cells expressing PD-1 and PD-L1, as well as the fraction of CD4<sup>+</sup> T cells expressing ICOS,  
262 increased slightly during treatment, while other checkpoint-expressing subsets remained stable over  
263 time. The relative expression of checkpoint molecules on CD4<sup>+</sup> and CD8<sup>+</sup> cells (i.e.,  $\Delta$ MFI) is shown in  
264 Supplementary Figure S3.


265 Based on the expression of memory marker CD45RO and lymphoid tissue homing chemokine  
266 receptor CCR7, we identified central memory (CD45RO<sup>+</sup>CCR7<sup>+</sup>), effector memory (CD45RO<sup>+</sup>CCR7<sup>-</sup>),  
267 and effector (CD45RO<sup>-</sup>CCR7<sup>-</sup>) cells within the CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets (Figure 2D). All memory  
268 and/or effector phenotypes within the CD4<sup>+</sup> and the CD8<sup>+</sup> subset appeared stable throughout  
269 radium-223 therapy.

270 Subsequently, we studied four immunosuppressive cell types: regulatory T cells (Tregs;  
271 CD3<sup>+</sup>CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup>), monocytic MDSCs (M-MDSCs; CD11b<sup>+</sup>CD14<sup>+</sup>CD15<sup>-</sup>HLA-DR<sup>low/-</sup>),  
272 polymorphonuclear MDSCs (PMN-MDSCs; CD11b<sup>+</sup>CD14<sup>-</sup>CD15<sup>+</sup>HLA-DR<sup>low/-</sup>), and early MDSCs (eMDSC;  
273 lin<sup>-</sup>CD14<sup>-</sup>CD15<sup>-</sup>CD33<sup>+</sup>HLA-DR<sup>low/-</sup>). PMN-MDSCs were not detected, likely because we used  
274 cryopreserved samples. While the portion of M-MDSCs and eMDSCs, as well as the subsets  
275 expressing PD-L1, remained stable during treatment, we observed a small increase in the Treg  
276 fraction (Figure 2E).

277

278 ***The uncertainty associated with the longitudinal changes in immune cell subsets***

279 To measure the degree of sampling variation in the described longitudinal changes of immune cell  
280 subsets during radium-223 treatment, we used a bootstrapping approach.  
281 We applied bootstrapping to the main T cell subsets (Figure 3A), the memory/effector T cell subsets  
282 (Figure 3B), and the immunosuppressive subsets (Figure 3C). With regard to the main T cell subsets,  
283 the bootstrap approach estimated an overall 6-month decrease of 20.3% (CI -31.8% - -8.8%) of the  
284 CD3<sup>+</sup> subset (Figure 3A).  
285  
286



287

288 **Figure 3: 6-Month change estimate of immune cell subsets during radium-223 therapy.**  
289 The percentage change relative to baseline is calculated using a bootstrap method. Per bootstrap, a linear  
290 model is fitted on the logit-transformed and normalized bootstrap sample. Subsequently, the model predictions  
291 at baseline and after six months are used to calculate the change in (A) CD3<sup>+</sup>, CD4<sup>+</sup>, and CD8<sup>+</sup> T cells, (B)  
292 memory/effector T cells, (C) immunosuppressive cells, and (D) checkpoint-expressing T cells and monocytes.

293

294 The changes in the CD4<sup>+</sup> and CD8<sup>+</sup> fractions of the CD3<sup>+</sup> subset were uncertain (Figure 3A). In the  
295 memory/effector T cell phenotypes, the largest change estimate was observed in the CD4<sup>+</sup>CD45RO<sup>+</sup>  
296 CCR7<sup>-</sup> subset (bootstrap estimate +15.1%, CI -4% – 42.9%). All other memory/effector phenotypes  
297 had less pronounced change estimates with CIs spanning across both positive and negative changes  
298 (Figure 3B). As indicated in Figure 3C, the proportion of Tregs in peripheral blood seemed to increase  
299 over time (25.1%; CI 14.3% - 38.2%). While the bootstrap estimate indicated an increase in the

300 fraction of M-MDSCs during therapy, the CI was wide (113.3%; CI 33.6% - 239.6%). In contrast to the  
301 other two immunosuppressive subsets, the eMDSC change estimate was inconclusive (9.9%; -36.9% -  
302 89.7%).

303 Concerning the checkpoint-expressing subsets, we observed a pronounced increase in the ICOS- and  
304 TIM-3-expressing proportion of CD4<sup>+</sup> and CD8<sup>+</sup> T cells, albeit with wide CIs (Figure 3D; numerical  
305 values are added as Supplementary Table S3). Less pronounced increases were seen in the fractions  
306 of PD-1- and PD-L1-expressing CD4<sup>+</sup> and CD8<sup>+</sup> T cells and PD-L1-expressing M-MDSCs. For the CTLA-4-  
307 and TIM-1-expressing subsets, changes were small (i.e., CD4<sup>+</sup>CTLA-4<sup>+</sup> and CD8<sup>+</sup>TIM-1<sup>+</sup>), and/or the  
308 sampling variation was large (Figure 3D). Interestingly, while the fraction of Tregs increased over  
309 time, the proportion of CTLA-4-expressing Tregs hardly changed.

310 In addition, the 6-month change in the relative expression of checkpoint molecules on lymphocytes  
311 and monocytes, as analyzed with the  $\Delta$ MFI, followed the same trend as the immune cell counts. The  
312 6-month change estimates of the  $\Delta$ MFI ranged from 0-10% (Supplementary Figure S4;  
313 Supplementary Table 4).

314

### 315 ***Subgroup analysis in patients with an ALP response***

316 Since our data indicated longitudinal changes in fractions of peripheral lymphocyte or monocyte  
317 subsets in the entire study population, and ALP changes are considered a surrogate marker for  
318 response to radium-223, we hypothesized that potential changes might be more pronounced in  
319 patients with an ALP response to radium-223 therapy (n=20; 67%). PBMCs for immunophenotyping  
320 were available on all time points for thirteen patients in this subset (Supplementary Figure S5).  
321 Visually, there is a strong resemblance between the subgroup with ALP responders and the entire  
322 population in terms of the occurrence of cells, their distribution, and time trends (Supplementary  
323 Figure S6). The bootstrapping approach supports this resemblance: we observed similar trends  
324 compared to the entire population, with higher uncertainty due to the smaller sample size  
325 (Supplementary Figure S7; Supplementary Table S5). Therefore, our data do not support a more

326 pronounced induction of fractions of immune cell subsets over time in patients with an ALP

327 response, compared to those without a biochemical response to radium-223 therapy.

328

## 329 DISCUSSION

330 In this prospective exploratory study, we performed a comprehensive evaluation of the  
331 immunological changes during radium-223 therapy by phenotyping PBMCs of 30 mCRPC patients.  
332 Overall, a substantial decrease in absolute lymphocyte counts was observed. While the total  
333 lymphocyte count decreased, we observed an increase in the proportion of T cells that expressed  
334 costimulatory (ICOS) or inhibitory (PD-L1, PD-1 and TIM-3) checkpoint molecules. In the  
335 immunosuppressive subsets, the proportion of Tregs and M-MDSCs increased during this study. A  
336 subgroup analysis in ALP responders indicated that the observed changes were not more  
337 pronounced in responding patients.

338 We observed a nearly two-fold decrease in absolute lymphocyte counts. In line with this, the  
339 fraction of CD3<sup>+</sup> T cells in PBMCs decreased. Although radium-223 is known to induce hematologic  
340 toxicity (neutropenia, thrombopenia) in a subset of patients, lymphopenia is not considered a  
341 common side effect of radium-223. Lymphopenia, defined as lymphocyte counts  $\leq 0.8 \times 10^9$ , was  
342 reported in only 1% of patients in the ALSYMPCA trial [16], whereas seventeen patients (56.7%) in  
343 our study developed lymphopenia during treatment. A possible explanation for the higher incidence  
344 of lymphopenia is the higher prevalence of patients with extensive bone metastases (i.e., >20 bone  
345 metastases in 83% of patients). In the pivotal ALSYMPCA trial, only 41% of patients had high volume  
346 bone metastatic disease. The decrease in lymphocyte counts might be a consequence of the direct  
347 cytotoxic effects of radium-223 on the bone marrow in patients with an already impaired bone  
348 marrow due to extensive bone metastases [17]. It is important to acknowledge that we only  
349 investigated circulating immune cells. We did not investigate changes in tumor-infiltrating immune  
350 cells. Therefore, it is unclear how the decrease in peripheral lymphocyte counts affects the number  
351 of tumor-infiltrating lymphocytes.

352 An increase was observed in the proportion of CD4<sup>+</sup> and CD8<sup>+</sup> T cells expressing immune  
353 checkpoint molecules PD-L1, ICOS, PD-1, or TIM-3. Checkpoint molecules play an essential role in the  
354 regulation of immune cell activity. ICOS is a costimulatory checkpoint molecule that enhances T cell

355 activation via binding to its ligand on antigen-presenting cells. PD-L1, PD-1, and TIM-3 are inhibitory  
356 checkpoint molecules. These checkpoint molecules inhibit T cell proliferation and activation to limit  
357 the immune response and maintain immune homeostasis. Although inhibitory checkpoint molecules  
358 are often considered markers of immune exhaustion, inhibitory checkpoint molecules are  
359 upregulated upon immune cell activation and are, therefore, also markers of immune activation  
360 [18,19]. Only one study in fifteen mCRPC patients has reported changes in checkpoint molecule  
361 expression during radium-223. Herein, PD-1<sup>+</sup> effector memory CD8<sup>+</sup> T cells decreased [8], while we  
362 observed a small increase in total CD8<sup>+</sup>PD-1<sup>+</sup> T cells. In line with our findings, studies with ionizing  
363 radiation show upregulation of checkpoint molecule expression in the tumor microenvironment.  
364 Several mice studies have described that PD-1 [20] and PD-L1 [21–23] are upregulated in the tumor  
365 microenvironment following irradiation and that combining irradiation with anti-PD-(L)1 improved  
366 tumor control compared to either therapy alone. Oweida and colleagues observed an increase in  
367 ICOS and TIM-3 expression on tumor-infiltrating T cells during treatment with radiotherapy and PD-  
368 L1 blockade [24]. Moreover, a recent study in patients with head and neck cancer showed that PD-1  
369 and CTLA-4 expression on PBMCs increased following radiation therapy [9].

370 Besides the increase in the fraction of checkpoint molecule-expressing T cells, we observed  
371 an increase in the proportion of two immunosuppressive subsets during radium-223 therapy (i.e.,  
372 Tregs and M-MDSCs). There is no data on the effect of radium-223 on Tregs or M-MDSCs, but several  
373 studies have reported that ionizing radiation can lead to the accumulation of circulating and tumor-  
374 infiltrating Tregs [9,24–26] and MDSCs [27], supporting our findings here.

375 It is unclear how the changes observed during radium-223 affect antitumor immunity. We  
376 hypothesized that radium-223 would lead to immune cell activation. However, except for the  
377 increase in the fraction of ICOS-expressing T cells, our findings – specifically, the relative increase in  
378 Tregs and M-MDSCs and the upregulation of inhibitory checkpoints molecules – are associated with  
379 immune suppression. It is possible that the relative increase in Tregs, M-MDSCs, and checkpoint-  
380 expressing T cells prevents excessive immune activity during radium-223 therapy or reflects the

381 migration of (non-exhausted) effector T cells into the tumor [28]. Given these hypotheses, it might be  
382 effective to combine radium-223 with immunotherapy due to synergistic effects on the immune  
383 system. Another possibility is that the relative increase in immunosuppressive cells and the  
384 upregulation of inhibitory checkpoint molecules during radium-223 therapy abrogate the immune-  
385 promoting effects of radium-223 and inhibit an effective antitumor immune response. In the latter  
386 case, treatment strategies combining radium-223 with immune-based therapies might not be  
387 effective unless we are informed about the most critical immunosuppressive mechanisms in these  
388 patients and can overcome them.

389 Knowledge of the immunological effects of radium-223 is vital to improve the care for  
390 patients with mCRPC. Although Sipuleucel-T – a cellular immunotherapy – is registered for the  
391 treatment of mCRPC [29], checkpoint inhibitor monotherapy could not induce clinically meaningful  
392 responses in unselected cohorts of mCRPC patients [30–32]. While checkpoint inhibitor monotherapy  
393 is not the way forward for all mCRPC patients, checkpoint inhibitors may be of value in specific  
394 subgroups (NCT04104893) [33–35] or in combination with other therapies (NCT02861573).  
395 Subgroups of interest include patients with a high tumor mutational burden [34] or DNA damage  
396 repair deficiency [35–37]. The data on combination strategies of radium-223 with immunotherapy is  
397 scarce. In a randomized phase II trial, including 32 mCRPC patients, the combination of sipuleucel-T  
398 with radium-223 was found to increase median progression-free survival compared to sipuleucel-T  
399 alone (10.7 versus 3.1 months; HR 0.35, 95% CI 0.15-0.81;  $p=0.02$ ). PSA responses were more  
400 frequently observed in the combination arm (33% versus 0%) [38], supporting the idea that radium-  
401 223 promotes antitumor immunity. Results from a recent single-arm, phase Ib trial indicated a  
402 limited efficacy of radium-223 in combination with PD-L1 inhibitor atezolizumab, with confirmed  
403 objective response rates of only 6.8% and PSA responses in 4.5% of patients [39]. Other phase II trials  
404 combining radium-223 with checkpoint inhibitors are ongoing (NCT02814669, NCT03093428,  
405 NCT04109729, NCT04071236).

406           This study has some limitations. We did not include a control arm consisting of mCRPC  
407 patients that did not receive radium-223 therapy. Therefore, it remains uncertain if the observed  
408 immunological changes are indeed a result of radium-223 therapy. The observed changes may be a  
409 consequence of disease progression rather than an effect of radium-223. Another constraint is that  
410 we did not investigate changes in tumor-infiltrating immune cells. Therefore, it remains unclear  
411 whether changes in the composition and abundance of circulating immune cells reflect changes in  
412 tumor-infiltrating lymphocytes. It is difficult to interpret our results without knowledge of changes in  
413 tumor-infiltrating immune cells. Further research should uncover how the observed changes in  
414 PBMCs correlate with changes in the tumor microenvironment. A third limitation is the small sample  
415 size relative to the number of markers being studied.

416           In summary, we observed a decrease in absolute lymphocyte counts and an increase in the  
417 proportion of checkpoint-expressing T cells, Tregs, and M-MDSCs. Our findings provide initial insights  
418 into the temporal dynamics of immune cell subsets in mCRPC patients and guide further research  
419 into radium-223-induced immune mechanisms. A thorough understanding of these mechanisms  
420 might pave the way toward optimizing treatment timing and effective combination strategies.

421 **DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST**

422 M.J. van der Doelen received research grants from Bayer (to institution) during the conduct of the  
423 study, travel expenses from Bayer, research grants from Janssen Pharmaceuticals, and personal fees  
424 from Astellas outside the submitted work. R. Hermsen is member of the advisory board of Bayer and  
425 received personal fees and travel expenses from Bayer outside the submitted work. D.M. Somford is  
426 a member of the advisory boards of Janssen Pharmaceuticals, Astellas and Bayer and received  
427 research grants from Astellas outside the submitted work. N. Mehra is a member of the advisory  
428 boards of Bayer, Bristol Myers Squibb, Roche, Merck Sharp and Dohme, Astellas and Janssen  
429 Pharmaceuticals, and reports personal fees from Bayer, research grants and personal fees from  
430 Janssen Pharmaceuticals, research grants and personal fees from Merck Sharp and Dohme, research  
431 grants and personal fees from Roche, research grants and personal fees from Astellas, research  
432 grants and personal fees from AstraZeneca, research grants and personal fees from Sanofi, research  
433 grants from Pfizer and research grants from Genzyme outside the submitted work. No potential  
434 conflicts of interest were disclosed by the other authors.

435

436 **ACKNOWLEDGEMENTS**

437 We thank all patients and their families who participated in this study. We thank Merijn Janssen,  
438 Marga Ouwens, Marjo van de Ven, Maarten de Bakker, and Maarten Vincken for the collection of the  
439 blood samples.

440

441 **FUNDING**

442 This research was partly funded by Bayer The Netherlands. The funding organization had no role in  
443 the design and conduct of the study, collection, management, analysis, interpretation of the data,  
444 and preparation, review, or approval of the abstract or the manuscript.

445 **REFERENCES**

- 446 1. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, Chodacki A, Wiechno P,  
447 Logue J, Seke M, et al.: **Alpha Emitter Radium-223 and Survival in Metastatic Prostate**  
448 **Cancer.** *N Engl J Med* 2013, **369**(3):213–223.
- 449 2. Morris MJ, Corey E, Guise TA, Gulley JL, Kevin Kelly W, Quinn DI, Scholz A, Sgouros G: **Radium-**  
450 **223 mechanism of action: implications for use in treatment combinations.** *Nat Rev Urol*  
451 2019, **16**(12):745–756.
- 452 3. Ritter MA, Cleaver JE, Tobias CA: **High-LET radiations induce a large proportion of non-**  
453 **rejoining DNA breaks.** *Nature* 1977, **266**(5603):653–655.
- 454 4. Suominen MI, Fagerlund KM, Rissanen JP, Konkol YM, Morko JP, Peng ZQ, Alhoniemi EJ, Laine  
455 SK, Corey E, Mumberg D, et al.: **Radium-223 inhibits osseous prostate cancer growth by dual**  
456 **targeting of cancer cells and bone microenvironment in mouse models.** *Clin Cancer Res*  
457 2017, **23**(15):4335–4346.
- 458 5. Abou DS, Ulmert D, Doucet M, Hobbs RF, Riddle RC, Thorek DLJ: **Whole-Body and**  
459 **Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate**  
460 **Cancer Metastasis.** *J Natl Cancer Inst* 2016, **108**(5):djv380.
- 461 6. Wu Q, Allouch A, Martins I, Brenner C, Modjtahedi N, Deutsch E, Perfettini JL: **Modulating**  
462 **both tumor cell death and innate immunity is essential for improving radiation therapy**  
463 **effectiveness.** *Front Immunol* 2017, **8**:613.
- 464 7. Malamas AS, Gameiro SR, Knudson KM, Hodge JW: **Sublethal exposure to alpha radiation**  
465 **(223Ra dichloride) enhances various carcinomas’ sensitivity to lysis by antigenspecific**  
466 **cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation.**  
467 *Oncotarget* 2016, **7**(52):86937–86947.
- 468 8. Kim JW, Shin MS, Kang Y, Kang I, Petrylak DP: **Immune Analysis of Radium-223 in Patients**  
469 **With Metastatic Prostate Cancer.** *Clin Genitourin Cancer* 2018, **16**(2):e469–e476.
- 470 9. Balázs, Kis, Badie, Bogdándi, Candéias, Garcia, Dominczyk, Frey, Gaipl, Jurányi, et al.:  
471 **Radiotherapy-Induced Changes in the Systemic Immune and Inflammation Parameters of**  
472 **Head and Neck Cancer Patients.** *Cancers (Basel)* 2019, **11**(9):1324.
- 473 10. Schwartz LH, Litière S, De Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen  
474 A, Dancey J, et al.: **RECIST 1.1 - Update and clarification: From the RECIST committee.** *Eur J*  
475 *Cancer* 2016, **62**:132–137.
- 476 11. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM,  
477 Carducci MA, Chi KN, et al.: **Trial Design and Objectives for Castration-Resistant Prostate**  
478 **Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group**  
479 **3.** *J Clin Oncol* 2016, **34**(12):1402–18.
- 480 12. Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, Grolemund G, Hayes A,  
481 Henry L, Hester J, et al.: **Welcome to the Tidyverse.** *J Open Source Softw* 2019, **4**(43):1686.
- 482 13. Wickham H, Dana S: *scales: Scale Functions for Visualization.* 2020.
- 483 14. Wilke CO: *cowplot: Streamlined Plot Theme and Plot Annotations for “ggplot2.”* 2019.
- 484 15. Clarke E, Sherrill-Mix, S: *ggbeeswarm: Categorical Scatter (Violin Point) Plots.* 2017.
- 485 16. Vogelzang NJ, Coleman RE, Michalski JM, Nilsson S, O’Sullivan JM, Parker C, Widmark A,  
486 Thuresson M, Xu L, Germino J, et al.: **Hematologic Safety of Radium-223 Dichloride: Baseline**  
487 **Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial.** *Clin*  
488 *Genitourin Cancer* 2017, **15**(1):42-52. e8.
- 489 17. Fiz F, Sahbai S, Campi C, Weissinger M, Dittmann H, Marini C, Piana M, Sambuceti G, Fougère  
490 C La: **Tumor Burden and Intraosseous Metabolic Activity as Predictors of Bone Marrow**  
491 **Failure during Radioisotope Therapy in Metastasized Prostate Cancer Patients.** *Biomed Res*  
492 *Int* 2017, **2017**:3905216.
- 493 18. Qin S, Xu L, Yi M, Yu S, Wu K, Luo S: **Novel immune checkpoint targets: moving beyond PD-1**  
494 **and CTLA-4.** *Mol Cancer* 2019, **18**(1):155.
- 495 19. Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías  
496 LD, et al.: **Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small**

- 497 cell lung cancer using spatially resolved and multiparametric single-cell analysis. *Clin Cancer*  
498 *Res* 2019, **25**(15):4663–4673.
- 499 20. Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL, Labiano S,  
500 Sanmamed MF, Azpilikueta A, Bolaños E, et al.: **Abscopal effects of radiotherapy are**  
501 **enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and**  
502 **crosspriming.** *Cancer Res* 2016, **76**(20):5994–6005.
- 503 21. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX: **Irradiation and**  
504 **anti-PD-L1 treatment synergistically promote antitumor immunity in mice.** *J Clin Invest* 2014,  
505 **124**(2):687–695.
- 506 22. Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, Nuryadi E, Sekine R, Oike T,  
507 Kakoti S, et al.: **DNA double-strand break repair pathway regulates PD-L1 expression in**  
508 **cancer cells.** *Nat Commun* 2017, **8**(1):1751.
- 509 23. Wu C Te, Chen WC, Chang YH, Lin WY, Chen MF: **The role of PD-L1 in the radiation response**  
510 **and clinical outcome for bladder cancer.** *Sci Rep* 2016, **6**:19740.
- 511 24. Oweida A, Hararah MK, Phan A, Binder D, Bhatia S, Lennon S, Bukkapatnam S, Van Court B,  
512 Uyanga N, Darragh L, et al.: **Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by**  
513 **TIM-3 Upregulation and Regulatory T-Cell Infiltration.** *Clin Cancer Res* 2018, **24**(21):5368–  
514 5380.
- 515 25. Muroyama Y, Nirschl TR, Kochel CM, Lopez-Bujanda Z, Theodros D, Mao W, Carrera-Haro MA,  
516 Ghasemzadeh A, Marciscano AE, Velarde E, et al.: **Stereotactic Radiotherapy Increases**  
517 **Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.** *Cancer*  
518 *Immunol Res* 2017, **5**(11):992–1004.
- 519 26. Kachikwu EL, Iwamoto KS, Liao Y-P, DeMarco JJ, Agazaryan N, Economou JS, McBride WH,  
520 Schae D: **Radiation enhances regulatory T cell representation.** *Int J Radiat Oncol Biol Phys*  
521 2011, **81**(4):1128–35.
- 522 27. Xu J, Escamilla J, Mok S, David J, Priceman S, West B, Bollag G, McBride W, Wu L: **CSF1R**  
523 **signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of**  
524 **radiotherapy in prostate cancer.** *Cancer Res* 2013, **73**(9):2782–2794.
- 525 28. Krieg C, Nowicka M, Guglietta S, Schindler S, Hartmann FJ, Weber LM, Dummer R, Robinson  
526 MD, Levesque MP, Becher B: **High-dimensional single-cell analysis predicts response to anti-**  
527 **PD-1 immunotherapy.** *Nat Med* 2018, **24**(2):144–153.
- 528 29. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC,  
529 Dreicer R, Sims RB, et al.: **Sipuleucel-T Immunotherapy for Castration-Resistant Prostate**  
530 **Cancer.** *N Engl J Med* 2010, **363**(5):411–422.
- 531 30. Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, Vaishampayan U,  
532 Berger R, Sezer A, Alanko T, et al.: **Pembrolizumab for treatment-refractory metastatic**  
533 **castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study.** *J*  
534 *Clin Oncol* 2020, **38**(5):395–405.
- 535 31. Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F,  
536 Humanski P, et al.: **Randomized, double-blind, phase III trial of ipilimumab versus placebo in**  
537 **asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive**  
538 **castration-resistant prostate cancer.** *J Clin Oncol* 2017, **35**(1):40–47.
- 539 32. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, Van den Eertwegh AJM, Krainer M, Houede N,  
540 Santos R, Mahammedi H, et al.: **Ipilimumab versus placebo after radiotherapy in patients**  
541 **with metastatic castration-resistant prostate cancer that had progressed after docetaxel**  
542 **chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial.** *Lancet*  
543 *Oncol* 2014, **15**(7):700–712.
- 544 33. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, de Jesus-Acosta A, Delord JP, Geva R,  
545 Gottfried M, Penel N, Hansen AR, et al.: **Efficacy of pembrolizumab in patients with**  
546 **noncolorectal high microsatellite instability/ mismatch repair-deficient cancer: Results from**  
547 **the phase II KEYNOTE-158 study.** *J Clin Oncol* 2020, **38**(1):1–10.
- 548 34. van Dessel LF, van Riet J, Smits M, Zhu Y, Hamberg P, van der Heijden MS, Bergman AM, van

- 549 Oort IM, de Wit R, Voest EE, et al.: **The genomic landscape of metastatic castration-resistant**  
550 **prostate cancers reveals multiple distinct genotypes with potential clinical impact.** *Nat*  
551 *Commun* 2019, **10**(1):1–13.
- 552 35. Nombela P, Lozano R, Aytes A, Mateo J, Olmos D, Castro E: **BRCA2 and other DDR genes in**  
553 **prostate cancer.** *Cancers (Basel)* 2019, **11**(3):352.
- 554 36. Sharma P, Pachynski RK, Narayan V, Flechon A, Gravis G, Galsky MD, Mahammedi H, Patnaik  
555 A, Subudhi SK, Ciprotti M, et al.: **Initial results from a phase II study of nivolumab (NIVO) plus**  
556 **ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer**  
557 **(mCRPC; CheckMate 650).** *J Clin Oncol* 2019, **37**(7\_suppl):142–142.
- 558 37. Hsiehchen D, Hsieh A, Samstein RM, Wang T, Morris LGT, Correspondence HZ, Lu T, Beg MS,  
559 Gerber DE, Zhu H: **DNA Repair Gene Mutations as Predictors of Immune Checkpoint**  
560 **Inhibitor Response beyond Tumor Mutation Burden II.** *Cell Rep Med* 2020, **1**(3):100034.
- 561 38. Marshall CH, Park JC, DeWeese TL, King S, Afful M, Hurrelbrink J, Manogue C, Cotogno P,  
562 Moldawer NP, Barata PC, et al.: **Randomized phase II study of sipuleucel-T (SipT) with or**  
563 **without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant**  
564 **prostate cancer (mCRPC).** *J Clin Oncol* 2020, **38**(6\_suppl):130–130.
- 565 39. Morris MJ, Fong L, Petrylak DP, Sartor AO, Higano CS, Pagliaro LC, Alva AS, Appleman LJ, Tan  
566 W, Vaishampayan UN, et al.: **Safety and clinical activity of atezolizumab (atezo) + radium-223**  
567 **dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results**  
568 **from a phase Ib clinical trial.** *J Clin Oncol* 2020, **38**(15\_suppl):5565–5565.  
569